CPT2

Across TCGA pan-cancer cohorts, CPT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CPT2 data layer compared with 17 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CPT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CPT2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

LUAD, CCRCC, and COAD are the cancer types where CPT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.286	0.779	<.001	27	view →
CCRCC	DFS	Tertile	II,III,IV	0.904	0.105	.008	13	view →
COAD	DFS	Median	III,IV	1.000	0.844	.044	6	view →
PDAC	OS	Quartile	All	0.590	0.362	.032	4	view →
LSCC	OS	Quartile	All	0.942	0.730	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CPT2–LUAD (DFS)

Open the LUAD breakdown →